Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies

Viruses are masters of disguise, constantly shifting their appearance to evade the immune system's defenses. When a virus like SARS-CoV-2 infects a person, the body produces antibodies, which are Y-shaped proteins designed to latch onto specific parts of the virus and neutralize it. Scientists have long hoped to find antibodies that target the most unchangeable parts of a virus, the structural components so essential to the virus's survival that it cannot afford to mutate them without dying. One such critical component is a region on the virus's surface spike protein called the HR2 stem helix. This area acts like a mechanical lever that the virus uses to fuse with human cells and deliver its genetic material. Because this lever is so vital, it remains largely the same across different variants of the virus, making it an attractive target for a universal vaccine or a long-lasting treatment. However, finding antibodies that can effectively lock this lever in place has proven difficult, as the immune system often struggles to generate strong responses against these hidden, conserved regions.

Researchers set out to understand how the human immune system learns to fight this specific part of the virus over time. They followed a group of people who had recovered from SARS-CoV-2 infection, collecting blood samples from them over a period of thirty months. The goal was to see if the body's antibodies against the HR2 stem helix became stronger, broader, or more effective as time passed and the individuals were exposed to the virus again through infection or vaccination. The team isolated specific antibodies from the blood of two individuals who had shown strong immune responses. They compared these new antibodies, collected a year and a half and two and a half years after the initial infection, with an antibody they had already discovered early in the pandemic, known as hr2.016. This earlier antibody was already known to be very potent, capable of neutralizing a wide range of viral variants.

The scientists found that while the immune system continued to produce antibodies against the HR2 stem helix over the long term, these new antibodies did not surpass the performance of the early one. Even though the new antibodies had accumulated more genetic mutations, a process that usually helps them become better at their job, they were not any better at neutralizing the virus. In fact, none of the antibodies found later in the study were significantly more powerful or versatile than hr2.016. This was surprising because it suggested that simply waiting for the immune system to mature over time does not automatically lead to better protection at this specific site. The researchers then looked closely at the structure of these antibodies to understand why some worked well and others did not. They examined four different antibodies, including the powerful hr2.016 and a close relative called hr2.086, which came from the same family of immune cells but failed to neutralize the virus effectively.

Structurally, these two antibodies looked almost identical. They both latched onto the same spot on the virus's stem helix with nearly the same shape and grip. If the immune system were a lock and key mechanism, these two keys would look the same and fit into the same lock. Yet, one key turned the lock and stopped the virus, while the other did nothing. The difference lay not in how they grabbed the virus, but in how long they held on. Using a technique that measures how fast molecules bind and unbind, the researchers discovered that hr2.016 stayed attached to the virus for about four and a half hours, whereas hr2.086 let go in less than an hour. This difference in staying power was the deciding factor. The longer an antibody remains attached, the more likely it is to interfere with the virus's ability to change shape and fuse with a cell.

To understand why one antibody held on so much longer, the team ran computer simulations that modeled the molecular interactions between the antibodies and the virus. These simulations revealed that hr2.016 formed a more stable and tightly organized network of connections with the virus, particularly at the end of the target region. This stability made it harder for the virus to shake the antibody loose. In contrast, hr2.086 had a more flexible connection that allowed it to detach more easily. The researchers also tested how the antibodies behaved when they were in their natural, two-pronged form, which allows them to grab the virus with both arms at once. They found that this double grip, known as avidity, further extended the time hr2.016 stayed attached, reinforcing its ability to neutralize the virus. The weaker antibody, even with two arms, could not maintain a hold long enough to stop the infection.

The study concludes that for antibodies targeting this specific, conserved part of the virus, the speed at which they let go is just as important as how well they fit. A strong, long-lasting grip is required to effectively block the virus from entering cells. This finding challenges the idea that the immune system will naturally produce better antibodies over time simply by accumulating mutations. Instead, it suggests that the most effective antibodies are those that happen to develop a specific kinetic stability early on. For scientists designing new vaccines or treatments, this means that the search for a universal solution should focus not just on finding antibodies that bind to the right spot, but on finding those that stay attached long enough to do their job. The antibody hr2.016, which emerged early in the infection and maintained its superior grip, stands out as a promising candidate for further development, offering a blueprint for how to target the virus's most vulnerable and unchanging machinery.